Homologous boosting with adenoviral serotype 5 HIV Vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Sarwar, Uzma N ^a   Novik, Laura ^a   Enama, Mary E ^a   Plummer, Sarah A ^a   Koup, Richard A ^a   Nason, Martha C ^a   Bailer, Robert T ^a   McDermott, Adrian B ^a   Roederer, Mario ^a   Mascola, John R ^a   Ledgerwood, Julie E ^a   Graham, Barney S ^a   Adams, Elizabeth ^a   Berkowitz, Nina ^b   Casazza, Joseph ^b   Costner, Pamela ^b   Gordon, Ingelise ^b   Hendel, Cynthia Starr ^b   Holman, Lasonji ^b   Larkin, Brenda ^b   Leitman, Susan ^c   Mendoza, Floreliz ^b   Saunders, Jamie ^b   Sitar, Sandra ^b   Wilson, Brandon ^b   Zephir, Kathryn ^b   Conan Cibotti, Michelle ^b   DeCederfelt, Hope ^c   Starling, Judith ^b   Renehan, Phyllis ^d   Kunchai, Meghan ^d   Diep, Ly ^d   Vasilenko, Olga ^b   Yamshchikov, Galina ^b   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Vaccine Research Center   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADENOVIRUS; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MIDDLE AGED; NEEDLE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION REACTION; YOUNG ADULT; ADENOVIRIDAE; ADOLESCENT; BIOSYNTHESIS; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; IMMUNOLOGY;

ADENOVIRIDAE; ADOLESCENT; ADULT; AIDS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HIV ANTIBODIES; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84907502907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106240     Document Type: Article

References (35)

1. Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, et al. (2001) Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19: 4703-4709
2. Aguiar JC, Hedstrom RC, Rogers WO, Charoenvit Y, Sacci JB Jr, et al. (2002) Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 20: 275-280
3. Graham BSGMEE, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, et al. (2013) DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after a rAd5 boost in a randomized clinical trial PLoS One: In press
4. Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, et al. (2000) Hepatitis A vaccine administration: Comparison between jet-injector and needle injection. Vaccine 18: 1939-1943
5. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, et al. (2011) AWest Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 203: 1396-1404
6. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. (2011) DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect Dis 11: 916-924
7. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194: 1650-1660
8. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, et al. (2007) A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196: 1732-1740
9. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, et al. (2008) A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26: 6338-6343
10. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, et al. (2013) DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 8: e59340
11. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, et al. (2013) Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med
12. Lasaro MO, Ertl HC (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339
13. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25868
14. Limbach KJ, Richie TL (2009) Viral vectors in malaria vaccine development. Parasite Immunol 31: 501-519
15. Barbosa RP, Filho BG, Dos Santos LI, Junior PA, Marques PE, et al. (2013) Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS One 8: e61795
16. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, et al. (2010) A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29: 304-313
17. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, et al. (2011) HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 187: 3391-3401
18. Cheng C, Gall JG, Nason M, King CR, Koup RA, et al. (2010) Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84: 630-638
19. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893
20. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, et al. (2010) Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE 5: e13579
21. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649
22. Moodie Z, Huang Y, Gu L, Hural J, Self SG (2006) Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 315: 121-132
23. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. (2010) Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5: e12873
24. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, et al. (2010) A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 201: 600-607
25. Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, et al. (2003) Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315: 345-352
26. Levine MM (2003) Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9: 99-103
27. Mathei C, Van Damme P, Meheus A (1997) Hepatitis B vaccine administration: Comparison between jet-gun and syringe and needle. Vaccine 15: 402-404
28. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, et al. (2002) Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 13: 1551-1560
29. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18: 1213-1216
30. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV- 1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372: 1894-1905
31. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, et al. (2011) A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS One 6: e21225
32. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, et al. (2011) Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial. PLoS One 6: e24517
33. Musey L, Hughes J, Schacker T, Shea T, Corey L, et al. (1997) Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 337: 1267-1274
34. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860
35. Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, et al. (1996) Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 70: 5799-5806.